Patent EP0509833A1 successfully refreshed from Google Patents.
EP0509833A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
An intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
Assignee: Koken Co Ltd
•
Filing: 1992-04-16
•
Granted: —
•
Expires: 2012-04-16
Abstract
Abstract The present invention provides an intracorporeally injectable non-toxic composition of atelocollagen having an excellent, long-lasting skin swelling effect due to its low viscosity, good fluidity, easy injectability and low antigenicity (without calcification) properties. The composition is prepared by treating an aqueous suspension of atelocollagen with a buffer for physiological conditions. The suspension can have an atelocollagen content of 55 to 75 mg/ml, where approximately 20 to 100% by weight of the atelocollagen is cross-linked with a polyepoxy compound.
Inventors
- 👤 Teruo C/O Koken Bioscience Institute Miyata
- 👤 Tadatomo C/O Koken Bioscience Institute Kawai
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 16:45
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/24; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/39; A61L24/00; A61L24/04; A61L24/10; A61L24/102; A61F; A61F2310/00; A61F2310/00005; A61F2310/00365
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
45 words
An injectable composition comprising an aqueous suspension of atelocollagen which is buffered for use in physiological conditions comprises a concentration of 55 to 75 mg/ml of said atelocollagen in which 20 - 100% by weight of said atelocollagen has been cross-linked with a polyepoxy compound.
Claim 2
Dependent Claim
29 words
An injectable composition as claimed in claim 1, in which said cross-linked atelocollagen has a transition point of not less than 40°C as measured by a differential scanning calorimeter.
Claim 3
Dependent Claim
36 words
An injectable composition as claimed in any of the preceding claims, in which not less than 10% of amino groups side chains of atelocollagen molecules contained in said cross-linked atelocollagen are cross-linked with said polyepoxy compound.
Claim 4
Dependent Claim
69 words
An injectable composition as claimed in any of the preceding claims, wherein said polyepoxy compound is a member selected from the group consisting of glycerol diglycidyl ether, glycerol triglycidyl ether, diglycerol tetraglycidyl ether, triglycerol pentaglycidyl ether, poly (methylene glycol) diglycidyl ether (1-10 polymerization degree), poly (ethylene glycol) diglycidyl ether (1-10 polymerization degree), poly (trimethylene glycol) diglycidyl ether (1-8 polymerization degree), and poly (propylene glycol) diglycidyl ether (1-8 polymerization degree).
Claim 5
Dependent Claim
26 words
An injectable composition as claimed in any of the preceding claims, wherein said cross-linked collagen is cross-linked in an amount not less than 40% by weight.
Claim 6
Dependent Claim
20 words
An injectable composition as claimed in any of the preceding claims, wherein said polyepoxy compound is ethylene glycol diglycidyl ether.
Claim 7
Independent Claim
41 words
A method of improving the appearance of a human comprising administering to a tissue by injection a composition as claimed in any of the previous claims in an amount effective to achieve a cosmetically beneficial amount of swelling to said tissue.
References Cited (Backward Citations)
EP0089145A2
Cited
EP0132979A2
Cited
EP0212933A1
Cited
EP0306256A2
Cited
EP0330389A2
Cited
EP0411124A1
Cited
WO1990012055A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.